Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize the safety, tolerability and
dose-limiting toxicities (DLTs) for GR-MD-02 when administered intravenously to subjects with
biopsy-proven NASH with advanced liver fibrosis.